Camurus accepted as participant of the United Nations Global Compact
Camurus has been accepted as a participant of the United Nations Global Compact (UNGC)1, the world's largest sustainability network for companies. As a member, Camurus commits working to contribute to the UN's Sustainability Development Goals (SDGs) and the ten principles of the UNGC within the areas of human rights, labor law, environment and anti-corruption. For Camurus, the membership also offers the opportunity for knowledge exchange and networking.
"Camurus is already today working in accordance with the ten principles as our business concept of developing innovative medicines to improve the lives of patients with severe and chronic diseases has a clear sustainability perspective. The challenge is to conduct the work in the most sustainably way possible, both from a social, environmental and economic perspective – where UNGC has a guiding function.", says Iris Rehnström, Director Sustainability at Camurus. "The membership also increases the transparency of our sustainability work through increased reporting on our sustainability performance and progress within the different areas." she continues.
The key focus of Camurus’ sustainability work is to increase access to the company’s medicines for as many patients as possible, with products being produced and used in a sustainable way. By conducting an ambitious sustainability work throughout the company’s value chain, Camurus contributes to 6 out of 17 of the UN SDGs.
The UNGC includes more than 17,000 companies and 4,000 organizations from more than 160 countries, including several national networks.
More information about UN Global Compact: https://unglobalcompact.org/
More information about Camurus’ sustainability work: https://www.camurus.com/sustainability/
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
1. United Nations Global Compact: https://unglobalcompact.org/